SETBP1 and cancer: Due to its overexpression on cancer cells, several investigations used the third loop (L3) of transforming growth factor-α (TGF-α) to conjugate with protein antibodies [72,73,74,75], or full superantigen SEB to exert the toxic effect of a drug in the vicinity of cancers to achieve targeted cancer therapy [76].